These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38194219)

  • 1. Statins and thyroid eye disease (TED): a systematic review.
    Malboosbaf R; Maghsoomi Z; Emami Z; Khamseh ME; Azizi F
    Endocrine; 2024 Jul; 85(1):11-17. PubMed ID: 38194219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
    Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins in Graves Orbitopathy: A New Therapeutic Tool.
    Lanzolla G; Comi S; Cosentino G; Pakdel F; Marinò M
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S29-S39. PubMed ID: 38054983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid surgery for Graves' disease and Graves' ophthalmopathy.
    Liu ZW; Masterson L; Fish B; Jani P; Chatterjee K
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010576. PubMed ID: 26606533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [LIFESTYLE ADJUSTMENT AS THERAPEUTIC TOOL IN THYROID EYE DISEASE].
    Vashdi I; Gur Z
    Harefuah; 2022 Apr; 161(4):223-227. PubMed ID: 35466606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for thyroid eye disease.
    Hamed Azzam S; Kang S; Salvi M; Ezra DG
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012984. PubMed ID: 30480323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.
    Nilsson A; Tsoumani K; Planck T
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1325-1332. PubMed ID: 33560351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oral statin therapy on strabismus in patients with thyroid eye disease.
    Reynolds AL; Del Monte MA; Archer SM
    J AAPOS; 2018 Oct; 22(5):340-343. PubMed ID: 30075294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Graves' disease in patients with thyroid eye disease].
    Sviridenko NY; Sheremeta MS; Belovalova IM; Melnichenko GA
    Vestn Oftalmol; 2021; 137(6):128-135. PubMed ID: 34965078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.
    Covelli D; Vannucchi G; Campi I; Currò N; D'Ambrosio R; Maggioni M; Gianelli U; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2015 May; 100(5):1731-7. PubMed ID: 25751109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
    Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
    Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
    Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
    J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic indicators for the development of strabismus among patients with graves' ophthalmopathy.
    Lin TY; Li N; Yeh MW; Leung AM; Rootman DB
    J Clin Transl Endocrinol; 2017 Sep; 9():38-40. PubMed ID: 29067268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors of Thyroid Eye Disease.
    Lee MH; Chin YH; Ng CH; Nistala KRY; Ow ZGW; Sundar G; Yang SP; Khoo CM
    Endocr Pract; 2021 Mar; 27(3):245-253. PubMed ID: 33655885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
    Mohamed A; Tzoulis P; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):979-985. PubMed ID: 36251747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
    Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
    Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
    Poon SHL; Cheung JJ; Shih KC; Chan YK
    Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.